The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

@article{Youssef2002TheHR,
  title={The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease},
  author={Sawsan S Youssef and Olaf St{\"u}ve and Juan Carlos Patarroyo and Pedro J. Ruiz and Jennifer L. Radosevich and Eun Mi Hur and Manuel Bravo and Dennis J. Mitchell and Raymond A Sobel and Lawrence Steinman and Scott S. Zamvil},
  journal={Nature},
  year={2002},
  volume={420},
  pages={78-84}
}
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, which are approved for cholesterol reduction, may also be beneficial in the treatment of inflammatory diseases. Atorvastatin (Lipitor) was tested in chronic and relapsing experimental autoimmune encephalomyelitis, a CD4+ Th1-mediated central nervous system (CNS) demyelinating disease model of multiple sclerosis. Here we show that oral atorvastatin prevented or reversed chronic and relapsing paralysis. Atorvastatin… CONTINUE READING
Highly Influential
This paper has highly influenced 33 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
388 Citations
35 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 388 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 35 references

a two-stage disease

  • Steinman, L. Multiple sclerosis
  • Nature Immunol. 2, 762–764
  • 2001

Similar Papers

Loading similar papers…